BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15780638)

  • 1. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
    Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
    Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
    Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
    Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
    Byth KF; Culshaw JD; Green S; Oakes SE; Thomas AP
    Bioorg Med Chem Lett; 2004 May; 14(9):2245-8. PubMed ID: 15081017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
    Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.
    Hamdouchi C; Keyser H; Collins E; Jaramillo C; De Diego JE; Spencer CD; Dempsey JA; Anderson BD; Leggett T; Stamm NB; Schultz RM; Watkins SA; Cocke K; Lemke S; Burke TF; Beckmann RP; Dixon JT; Gurganus TM; Rankl NB; Houck KA; Zhang F; Vieth M; Espinosa J; Timm DE; Campbell RM; Patel BK; Brooks HB
    Mol Cancer Ther; 2004 Jan; 3(1):1-9. PubMed ID: 14749470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
    J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY; Choi JW; Yang J; Chae CH; Lee J; Jung H; Lee K; Ha JD; Kim HR; Cho SY
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2837-42. PubMed ID: 22450128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
    Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
    Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
    J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
    Kim O; Jeong Y; Lee H; Hong SS; Hong S
    J Med Chem; 2011 Apr; 54(7):2455-66. PubMed ID: 21388141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
    Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functionalized 3-amino-imidazo[1,2-a]pyridines: a novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors.
    Odell LR; Nilsson MT; Gising J; Lagerlund O; Muthas D; Nordqvist A; Karlén A; Larhed M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4790-3. PubMed ID: 19560924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.